



Deal Sheet Summary – *Vectorized antibodies to alpha-synuclein*

Voyager Therapeutics and AbbVie

February 22, 2019

**Voyager
Therapeutics**

AbbVie

Collaboration Focus

Exclusive collaboration and option agreement to develop vectorized antibodies to alpha-synuclein for Parkinson's disease and other diseases

Option Rights

Upon completion of Ph1, AbbVie has option to license the mAb program

Financial Terms

\$65M Upfront payment
\$245M Preclinical & Ph1 option payments
\$728M Success-based milestones
\$500M Commercial milestones

Total Deal Value: >\$1 Billion plus tiered royalties global net sales

Responsibility

Research, IND-enabling and Ph1 and costs

Responsibility

Further clinical development
Global commercialization